Skip to main content
DARWIN AG logo

DARWIN AG — Investor Relations & Filings

Ticker · 7V0 ISIN · DE000A3C35W0 LEI · 391200XJOD6U0EW7OE14 MU Professional, scientific and technical activities
Open in API
Filings indexed 13 across all filing types
Latest filing 2026-05-12 Earnings Release
Country DE Germany
Listing MU 7V0

About DARWIN AG

https://darwin-biotech.com/

DARWIN AG is a biotechnology company specializing in personalized products, services, and therapies derived from individual biological data. The company leverages in-house technology platforms, including genetic and metabolomic laboratory analysis and artificial intelligence, to interpret unique biological markers. This "Analyse, Learn, Solve" approach is applied to develop a range of solutions. Key offerings include personalized dietary supplements and cosmetics formulated based on specific lab results. The company also provides genetic analysis for disease prevention, therapy optimization, and IVF improvement. Through a portfolio of brands and subsidiaries, DARWIN AG also engages in personalized drug development, gene therapies, and offers both B2B lab services and direct-to-consumer DNA and blood testing kits.

Recent filings

Filing Released Lang Actions
Darwin AG publishes financial figures and provides business update for 2025
Earnings Release Classification · 87% confidence The document is a corporate news release summarizing the full-year 2025 financial results (revenues, EBIT, net income, cash position) and providing business commentary and guidance. It does not present the full annual report with detailed financial statements or notes, nor does it merely announce the availability of a report. This matches the definition of an Earnings Release (ER). FY 2025
2026-05-12 English
Darwin AG to Present at Invest 2026 in Stuttgart and the Equity Forum in Frankfurt
Regulatory Filings Classification · 87% confidence The document is a corporate news announcement about Darwin AG presenting at investor conferences (Invest 2026 and the Equity Forum). It does not contain actual financial results, an AGM notice, a dividend declaration, management changes, or the text of a report or presentation. It is a generic corporate announcement/fallback notice, matching our “Regulatory Filings” (RNS) category.
2026-04-09 English
Darwin AG launches commercialization of Multi-Cancer Check a blood test for early detection of 13 types of cancer
Regulatory Filings Classification · 95% confidence The document is a corporate news release announcing the commercial launch of a new product ('Multi-Cancer Check') by Darwin AG. It provides details about the product, its development, and market context. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding business operations and product strategy, it falls under the 'Regulatory Filings' (RNS) category as the fallback for general corporate news.
2026-03-18 English
Darwin AG Announces Preliminary Group Revenue for 2025 and Confirms Strategic Growth Trajectory
Earnings Release Classification · 100% confidence The document is a short corporate news release (under 5,000 characters) announcing preliminary financial results (revenue and net result) for the 2025 fiscal year. It explicitly states that the full audited financial figures and the Annual Report will be published at a later date (May 12, 2026). Since this is an initial announcement of key financial highlights rather than the full report itself, it is classified as an Earnings Release. FY 2025
2026-02-25 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Darwin AG for the fiscal year 2024. It includes a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), notes (Anhang), and an independent auditor's report (Bestätigungsvermerk des unabhängigen Abschlussprüfers). While it contains audit information, it is the full statutory annual financial statement rather than a standalone audit report. In the context of German corporate filings, this constitutes the official annual report (Jahresabschluss), which maps to the 10-K category for comprehensive annual financial performance reporting. FY 2024
2025-08-22 German
Datum:30.07.2025
Annual Report Classification · 100% confidence The document is a 'Konzernabschluss' (Consolidated Financial Statement) for Darwin AG for the fiscal year 2024. It includes a report from the supervisory board (Bericht des Aufsichtsrats), a consolidated income statement (Konzern- Gewinn- und Verlustrechnung), a consolidated balance sheet (Konzernbilanz), and a statement of changes in equity (Konzerneigenkapitalspiegel). Since it contains comprehensive financial statements for a full fiscal year, it is classified as an Annual Report (10-K). FY 2024
2025-07-30 German

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.